Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : OTC:BB- JRSE -- Ignore unavailable to you. Want to Upgrade?

To: vcap who wrote (19)	10/12/1998 11:35:00 AM
From: Lance	Respond to of 72

Hello VCAP glad to see your still in JRSE and postin again..... Did Dr. Jacobson mention when he anticapates FDA approval. With 3 successful studies for nerve regeneration it seems like a no brainer that FDA has all the evidence they need. I wonder if the pending news will be something about the latest test study by Cornell. My buddy called the company and talked to COO Mr Chiovana of JRSE and he is very confident about getting FDA approval and was hoping for the end of this year or early '99 at latest and went on to say the results of the Cornell test studies were much better than anticapated and anticapates all this to be reflected in the stock price at which time JRSE will try to be listed on Nasdaq or AMEX.